EGFR and adenocarcinoma: Conversely, in its sole error in the assessed queries, the PDF+Prompt model recommended only Amivantamab for treatment of an EGFR exon 20 insertion adenocarcinoma, while neglecting to include carboplatin or pemetrexed.